Dmitri Kireev

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds
    Dmitri Kireev
    Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599 7363, United States
    J Med Chem 53:7625-31. 2010
  2. pmc Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis
    Weihe Zhang
    Center for Integrative Chemical Biology and Drug Discovery Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy Department of Pharmacology Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    J Med Chem 56:9693-700. 2013
  3. pmc UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor
    Weihe Zhang
    Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, Department of Pharmacology, School of Medicine, and Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    J Med Chem 57:7031-41. 2014
  4. pmc Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors
    Weihe Zhang
    Center for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    J Med Chem 56:9683-92. 2013

Collaborators

  • Stephen V Frye
  • Douglas K Graham
  • Jing Liu
  • Weihe Zhang
  • Minjung Lee
  • William P Janzen
  • Debra Hunter
  • Deborah DeRyckere
  • Susan Sather
  • Michael A Stashko
  • H Shelton Earp
  • Xiaodong Wang
  • Dehui Zhang
  • Yingqiu Zhou
  • Michael J Miley
  • Jacqueline Norris-Drouin
  • Mischa Machius
  • Wendy M Stewart
  • Trevor G Glaros
  • Katherine A Minson
  • Dianne L Newton
  • Christopher T Cummings
  • Brian R Branchford
  • Gregory Kirkpatrick
  • Christopher Cummings
  • Andrew L McIver
  • Jorge A Di Paola

Detail Information

Publications4

  1. pmc Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds
    Dmitri Kireev
    Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599 7363, United States
    J Med Chem 53:7625-31. 2010
    ..Nineteen of the purchased compounds showed a specific dose-dependent protein binding and will provide critical structure-activity information for subsequent lead generation and optimization...
  2. pmc Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis
    Weihe Zhang
    Center for Integrative Chemical Biology and Drug Discovery Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy Department of Pharmacology Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    J Med Chem 56:9693-700. 2013
    ..In addition, 23 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathologic thrombosis. ..
  3. pmc UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor
    Weihe Zhang
    Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, Department of Pharmacology, School of Medicine, and Lineberger Comprehensive Cancer Center, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    J Med Chem 57:7031-41. 2014
    ....
  4. pmc Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors
    Weihe Zhang
    Center for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    J Med Chem 56:9683-92. 2013
    ..The results provide a rationale for further investigation of this compound for therapeutic application in patients with cancer. ..